Stockreport

EHA 2024: Roche's Columvi competes in BiTE battle with positive results in DLBCL [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF The trial evaluated Roche's Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (Glofit-GemOx) against GemOx with Roche's MabThera/Rituxan (rituximab) ( [Read more]